Key Drivers
- Strong Margins
- Ample Liquidity
- High Valuation
AIAI Summary
LMAT now looks less like a simple steady medtech grower and more like a premium-priced, cash-generative niche compounder, but with the stock already discounting strong execution, the key test is whether management can keep driving pricing, mix and international growth—especially in Europe and via Artegraft—without triggering customer pushback or valuation compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Ample Liquidity
- •High Valuation
LMAT shows strong profitability, liquidity, cash generation, and manageable leverage, but its rich valuation and some capital intensity temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Weak momentum
LMAT has rolled over from an uptrend into a short-term downtrend, with repeated failures at $112-$115 and breaks below $107.91 and $101.64, leaving $97-$98 as the key support to hold.
Sharp decline from $114.36 to $97.31 with lower highs and lower lows
Sentiment & News
Key News Insights:
- •Q1 Beat
- •Bullish Upgrades
- •Oversold Pullback
LeMaitre Vascular beat Q1 earnings, boosted investor interest with a dividend and conference presentation, and saw analysts turn more bullish despite a recent oversold pullback and a small stake reduction.
The news is mildly positive overall, supporting a potential rebound if improved earnings estimates and operational momentum continue
Similar Companies in Healthcare
Other companies in the same sector with AI ratings